Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer

被引:16
|
作者
Daniels, Molly S. [1 ]
Urbauer, Diana L. [2 ]
Stanley, Jennifer L. [1 ]
Johnson, Kristin G. [3 ]
Lu, Karen H. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77230 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Quantitat Sci, Houston, TX 77230 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Nursing, Houston, TX 77230 USA
关键词
BRCA1; BRCA2; genetic testing; ovarian cancer; cancer recurrence; NONPOLYPOSIS COLORECTAL-CANCER; BRCA2; MUTATIONS; DNA-REPAIR; SURVIVAL; SUSCEPTIBILITY; PREVALENCE; POLYMERASE; INHIBITORS; CARCINOMA; FEATURES;
D O I
10.1097/GIM.0b013e3181ab2295
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: To determine when, in reference to the course of their treatment. women with ovarian cancer are seen for genetic Counseling. as well as to determine what factors influence this timing. Methods: Single institution retrospective chart review of patients with ovarian cancer Who Underwent BRCA1/BRCA2 genetic testing. Results: Thirty-three percent of our sample (n = 100) were seen for genetic counseling after ovarian cancer recurrence. In four cases, genetic test results were disclosed to next of kin. Thirty percent of women seen for genetic counseling after recurrence received their initial treatment elsewhere. Women with a history of breast cancer were significantly more likely to be seen for genetic counseling at an earlier phase of their treatment than women with no history of breast cancer. Conclusion: We found that one third of patients with ovarian cancer who underwent genetic testing were seen for initial genetic counseling after disease recurrence. In some cases, genetic counseling took place during the end of life care. with genetic test results disclosed to next of kin. Given the poor prognosis of women with recurrent ovarian cancer, we advocate providing genetic Counseling at the time of initial ovarian cancer treatment both in comprehensive cancer centers and in community oncology settings. Genet Med 2009:11(9):624-628.
引用
收藏
页码:624 / 628
页数:5
相关论文
共 50 条
  • [31] Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
    Pujol, Pascal
    Barberis, Massimo
    Beer, Philp
    Friedman, Eitan
    Piulats, Josep M.
    Capoluongo, Ettore D.
    Foncillas, Jesus Garcia
    Ray-Coquard, Isabelle
    Penault-Llorca, Frederique
    Foulkes, William D.
    Turnbull, Clare
    Hanson, Helen
    Narod, Steven
    Arun, Banu K.
    Aapro, Matti S.
    Mandel, Jean-Louis
    Normanno, Nicola
    Lambrechts, Diether
    Vergote, Ignace
    Anahory, Michele
    Baertschi, Bernard
    Baudry, Karen
    Bignon, Yves-Jean
    Bollet, Marc
    Corsini, Carole
    Cussenot, Olivier
    Rouge, Thibault De la Motte
    de Labarre, Marie Duboys
    Duchamp, Florence
    Duriez, Clarisse
    Fizazi, Karim
    Galibert, Virginie
    Gladieff, Laurence
    Gligorov, Joseph
    Hammel, Pascal
    Imbert-Bouteille, Marion
    Jacot, William
    Kogut-Kubiak, Tatiana
    Lamy, Pierre-Jean
    Nambot, Sophie
    Neuzillet, Yann
    Olschwang, Sylviane
    Rebillard, Xavier
    Rey, Jean-Marc
    Rideau, Chloe
    Spano, Jean-Philippe
    Thomas, Frederic
    Treilleux, Isabelle
    Vandromme, Marion
    Vendrell, Julie
    EUROPEAN JOURNAL OF CANCER, 2021, 146 : 30 - 47
  • [32] Clinical practice guidelines for BRCA1 and BRCA2 genetic testing
    Imbert-Bouteille, Marion
    Barberis, Massimo
    Beer, Philip
    Friedman, Eitan
    Piulats, Josep M.
    Capoluongo, Ettore D.
    Foncillas, Jesus Garcia
    Ray-Coquard, Isabelle
    Penault-Llorca, Frederique
    Foulkes, William D.
    Turnbull, Clare
    Hanson, Helen
    Narod, Steven
    Arun, Banu K.
    Aapro, Matti S.
    Mandel, Jean-Louis
    Normanno, Nicola
    Lambrechts, Diether
    Vergote, Ignace
    Baertschi, Bernard
    Baudry, Karen
    Bignon, Yves-Jean
    Bollet, Marc
    Corsini, Carole
    Cussenot, Olivier
    Rouge, Thibault De la Motte
    de Labarre, Marie Duboys
    Duchamp, Florence
    Duriez, Clarisse
    Fizazi, Karim
    Galibert, Virginie
    Gladieff, Laurence
    Gligorov, Joseph
    Hammel, Pascal
    Jacot, William
    Kogut-Kubiak, Tatiana
    Lamy, Pierre-Jean
    Nambot, Sophie
    Neuzillet, Yann
    Olschwang, Sylviane
    Rey, Jean-Marc
    Rideau, Chloe
    Spano, Jean-Philippe
    Thomas, Frederic
    Vandromme, Marion
    Vendrell, Julie
    Zarca, Daniel
    Hughes, Kevin S.
    Martinez, Jose E. Ales
    Pujol, Pascal
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2022, 30 (SUPPL 1) : 374 - 375
  • [33] Genetic testing for BRCA1 and BRCA2 mutations - ready for implementation?
    BL Weber
    Breast Cancer Research, 2 (Suppl 1)
  • [34] Population-Based Genetic Testing for BRCA1 and BRCA2
    Narod, Steven
    Akbari, Mohammad R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05) : 517 - +
  • [35] Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation
    Meijers-Heijboer, H
    Brekelmans, CTM
    Menke-Pluymers, M
    Seynaeve, C
    Baalbergen, A
    Burger, C
    Crepin, E
    van den Ouweland, AWM
    van Geel, B
    Klijn, JGM
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) : 1675 - 1681
  • [36] Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer
    Wenham, RM
    Schildkraut, JM
    McLean, K
    Calingaert, B
    Bentley, RC
    Marks, J
    Berchuck, A
    CLINICAL CANCER RESEARCH, 2003, 9 (12) : 4396 - 4403
  • [37] CONTRALATERAL MASTECTOMY AND BRCA1 AND BRCA2 Threshold for genetic testing in women with breast cancer needs to be determined
    Basu, Narendra Nath
    Barr, Lester
    Evans, D. Gareth
    Ross, Gary L.
    BMJ-BRITISH MEDICAL JOURNAL, 2014, 348
  • [38] Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations
    Ganguly, Shuvadeep
    Gogia, Ajay
    LANCET ONCOLOGY, 2022, 23 (07): : E314 - E314
  • [39] Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Hyman, David M.
    Spriggs, David R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 408 - 410
  • [40] Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer
    Ramus, Susan J.
    Harrington, Patricia A.
    Pye, Carole
    DiCioccio, Richard A.
    Cox, Mark J.
    Garlinghouse-Jones, Kim
    Oakley-Girvan, Ingrid
    Jacobs, Ian J.
    Hardy, Richard M.
    Whittemore, Alice S.
    Ponder, Bruce A. J.
    Piver, M. Steven
    Pharoah, Paul D. P.
    Gayther, Simon A.
    HUMAN MUTATION, 2007, 28 (12) : 1207 - 1215